Cingulate Inc.
Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
Manufacturing Work Addressing FDA CMC Information Requests Substantially Completed
Company newsroom
Cingulate Inc.
NASDAQ:CING
1 releases